- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of p...
HUTCHMED (China) Limited announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanc...
The development of cannabinoid and psychedelic medicines is entering a more evidence-driven phase, with clinical validation, safety, regulatory a...
10x Genomics, Inc., the life science technology leader focused on accelerating science and advancing human health, announced that a jury in the U.S. Dist...
Announcing expansion of capabilities to provide customers with a broader range of DNA synthesis solutions, allowing IDT to complement and extend ...
New Curitics Point of Care Solution, Ambient Listening, AI Care Management, and mobile capabilities help reduce administrative burden, strengthen care co...
MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development ...
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by po...
Responding to a growing number of patients seeking personalized cancer immunotherapy, Immunocine Cancer Center has opened a second treatment location in ...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces a breakthrough in RF resection technology for hip with its new FLOW FLE...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced to...
HUTCHMED (China) Limited announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO®...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed the sale of its microbiology business to ...
Cycle Pharmaceuticals (“Cycle”), a global pharmaceutical company focused on rare diseases, and Forma Life Sciences, Inc. (“Forma”...
© 2026 Biopharma Boardroom. All Rights Reserved.
